Bioventus Inc (OQ:BVS)

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEC
Company Contact
Address: 4721 EMPEROR BOULEVARD, SUITE 100
DURHAM NC 27703
Tel: N/A
Website: https://www.bioventus.com
IR: See website
<
Key People
Anthony P. Bihl
Interim Chief Executive Officer, Director
Mark Singleton
Chief Financial Officer, Senior Vice President
Katrina Church
Senior Vice President, Chief Compliance Officer
Anthony D'adamio
Senior Vice President, General Counsel
Sharon W. Klugewicz
Senior Vice President - Quality and Regulatory Affairs
 
Business Overview
Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body's natural healing process. Its portfolio of products is grouped into three verticals: Pain Treatments, Surgical Solutions, and Restorative Therapies. Its Pain Treatments consist of non-surgical joint pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions consists of bone graft substitutes (BGS) to fuse and grow bones and ultrasonic medical devices used for precise bone sculpting, removal of tumors, and tissue debridement in various surgeries, including spine and neurosurgery. Its Restorative Therapies consist of an ultrasonic bone healing system for fracture care, skin allografts and products used to support the healing of chronic wounds, as well as advanced rehabilitation devices.
Financial Overview
For the three months ended 01 April 2023, Bioventus Inc revenues increased 2% to $119.1M. Net loss before extraordinary items increased from $10.9M to $79.7M. Revenues reflect International segment increase of 14% to $15.1M. Higher net loss reflects Impairment of assets increase from $0K to $78.6M (expense), Int exp on Financial Lease Liabilities increase from $1K to $137K (expense).
Employees: 1,040 as of Apr 1, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $630.17M as of Apr 1, 2023
Annual revenue (TTM): $513.89M as of Apr 1, 2023
EBITDA (TTM): $72.33M as of Apr 1, 2023
Net annual income (TTM): -$227.09M as of Apr 1, 2023
Free cash flow (TTM): -$0.67M as of Apr 1, 2023
Net Debt Last Fiscal Year: $398.48M as of Apr 1, 2023
Shares outstanding: 78,273,462 as of May 12, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.